NP2

DB06308InvestigationalSmall molecule

NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer...

Mechanism: NP2 is the first drug developed for use in Diamyd Medical's Nerve Targeting Drug Delivery System (NTDDS) gene therapy platform to treat chronic pain associated with cancer. NP2 produces localized enkaphalins (endogenous pain killing compounds) at the synapses between the peripheral and central nervous system neurons.
Curator reviewed
Primary indication: Investigated for use/treatment in pain (acute or chronic).Curator reviewed

Resolves to

Targets

P00740F9

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with NP2, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account